Skip to main content
Top
Published in: Abdominal Radiology 7/2017

01-07-2017

Parametric response mapping of dynamic CT: enhanced prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization

Authors: Seung Joon Choi, Jonghoon Kim, Hyung Sik Kim, Hyunjin Park

Published in: Abdominal Radiology | Issue 7/2017

Login to get access

Abstract

Purpose

The aim of this study was to evaluate the prognostic significance of parametric response mapping (PRM) analysis for hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE).

Methods

We recruited 65 HCC patients who underwent TACE. These patients underwent longitudinal multiphasic CT before and after TACE. We applied PRM analysis to the baseline CT before TACE and first/second follow-up CTs. The results of PRM analyses were used to stratify patients into responders and non-responders. Overall survival was compared between the two groups. An independent survival analysis using conventional radiological assessments was performed, and the results were compared with PRM results. Univariate and multivariate analyses were performed to identify clinical factors affecting survival.

Results

The PRM analyses demonstrated that the responding group had a median survival of 529 days, while the non-responding group had a median survival of 263 days [hazard ratio (HR) 12.9, p < 0.05 for differences in survival]. The manual analyses indicated median survivals of 491 and 329 days for the responding and non-responding groups, respectively (HR 2.7, p < 0.05). Tumor size, albumin level, and PRM values were found to be significantly related to overall survival after univariate and multivariate analyses.

Conclusions

The PRM analysis could be a better predictor of overall survival for patients with HCC undergoing TACE than conventional radiological assessments.
Literature
1.
go back to reference Bosch FX, Ribes J, Díaz M, Cléries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(5):S5–S16CrossRefPubMed Bosch FX, Ribes J, Díaz M, Cléries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(5):S5–S16CrossRefPubMed
2.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108CrossRefPubMed Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108CrossRefPubMed
3.
go back to reference Jarnagin WR, Gonen M, Fong Y, et al. (2002) Improvement in perioperative outcome after hepatic resection: analysis of 1803 consecutive cases over the past decade. Ann Surg 236(4):397–406 ((Discussion 406–407))CrossRefPubMedPubMedCentral Jarnagin WR, Gonen M, Fong Y, et al. (2002) Improvement in perioperative outcome after hepatic resection: analysis of 1803 consecutive cases over the past decade. Ann Surg 236(4):397–406 ((Discussion 406–407))CrossRefPubMedPubMedCentral
4.
go back to reference Bruix J, Sala M, Llovet JM (2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology 127(5):S179–S188CrossRefPubMed Bruix J, Sala M, Llovet JM (2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology 127(5):S179–S188CrossRefPubMed
5.
go back to reference Llovet JM, Real MI, Montaña X, et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734–1739CrossRefPubMed Llovet JM, Real MI, Montaña X, et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734–1739CrossRefPubMed
6.
go back to reference Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2):429–442CrossRefPubMed Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2):429–442CrossRefPubMed
7.
go back to reference Cammà C, Schepis F, Orlando A, et al. (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224:47–54CrossRefPubMed Cammà C, Schepis F, Orlando A, et al. (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224:47–54CrossRefPubMed
8.
go back to reference Mabed M, Esmaeel M, El-Khodary T, Awad M, Amer T (2009) A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma. Eur J Cancer Care 18(5):492–499CrossRef Mabed M, Esmaeel M, El-Khodary T, Awad M, Amer T (2009) A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma. Eur J Cancer Care 18(5):492–499CrossRef
9.
go back to reference Ahsun R, Miller FH, Kulik LM, et al. (2010) Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. J Am Med Assoc 303(11):1062–1069CrossRef Ahsun R, Miller FH, Kulik LM, et al. (2010) Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. J Am Med Assoc 303(11):1062–1069CrossRef
10.
go back to reference Keppke AL, Salem R, Reddy D, et al. (2007) Imaging of hepatocellular carcinoma after treatment with Yttrium-90 microspheres. Am J Roentgenol 188(3):768–775CrossRef Keppke AL, Salem R, Reddy D, et al. (2007) Imaging of hepatocellular carcinoma after treatment with Yttrium-90 microspheres. Am J Roentgenol 188(3):768–775CrossRef
11.
go back to reference Gillmore R, Stuart S, Kirkwood A, et al. (2011) EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 55(6):1309–1316CrossRefPubMed Gillmore R, Stuart S, Kirkwood A, et al. (2011) EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 55(6):1309–1316CrossRefPubMed
12.
go back to reference Kim BK, Kim KA, Park JY, et al. (2013) Prospective comparison of prognostic values of modified response evaluation criteria in solid tumours with european association for the study of the liver criteria in hepatocellular carcinoma following chemoembolisation. Eur J Cancer 49(4):826–834CrossRefPubMed Kim BK, Kim KA, Park JY, et al. (2013) Prospective comparison of prognostic values of modified response evaluation criteria in solid tumours with european association for the study of the liver criteria in hepatocellular carcinoma following chemoembolisation. Eur J Cancer 49(4):826–834CrossRefPubMed
13.
go back to reference Suzuki C, Torkzad MR, Jacobsson H, et al. (2010) Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. Acta Oncol 49(4):509–514CrossRefPubMed Suzuki C, Torkzad MR, Jacobsson H, et al. (2010) Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. Acta Oncol 49(4):509–514CrossRefPubMed
14.
go back to reference Lencioni R, Llovet JM (2013) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Clin Cancer Res 19(6):1312–1314CrossRefPubMed Lencioni R, Llovet JM (2013) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Clin Cancer Res 19(6):1312–1314CrossRefPubMed
15.
go back to reference Forner A, Ayuso C, Varela M, et al. (2009) Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115:616–623CrossRefPubMed Forner A, Ayuso C, Varela M, et al. (2009) Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115:616–623CrossRefPubMed
16.
go back to reference Llovet JM, Mazzaferro V, Hilgard P, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed Llovet JM, Mazzaferro V, Hilgard P, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed
17.
go back to reference Galbán CJ, Chenevert TL, Meyer CR, et al. (2009) The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 15(5):572–576CrossRefPubMedPubMedCentral Galbán CJ, Chenevert TL, Meyer CR, et al. (2009) The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 15(5):572–576CrossRefPubMedPubMedCentral
18.
go back to reference Galbán CJ, Mukherji SK, Chenevert TL, et al. (2009) A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol 2(3):184–190CrossRefPubMedPubMedCentral Galbán CJ, Mukherji SK, Chenevert TL, et al. (2009) A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol 2(3):184–190CrossRefPubMedPubMedCentral
19.
go back to reference Kim MM, Lawrence TS, Cao Y (2015) Advances in magnetic resonance and positron emission tomography imaging: assessing response in the treatment of low-grade glioma. Semin Radiat Oncol 25(3):172–180CrossRefPubMedPubMedCentral Kim MM, Lawrence TS, Cao Y (2015) Advances in magnetic resonance and positron emission tomography imaging: assessing response in the treatment of low-grade glioma. Semin Radiat Oncol 25(3):172–180CrossRefPubMedPubMedCentral
20.
go back to reference Galbán CJ, Han MK, Boes JL, et al. (2012) Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med 18(11):1711–1715CrossRefPubMedPubMedCentral Galbán CJ, Han MK, Boes JL, et al. (2012) Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med 18(11):1711–1715CrossRefPubMedPubMedCentral
21.
go back to reference Boes JL, Hoff BA, Hylton N, et al. (2014) Image registration for quantitative parametric response mapping of cancer treatment response. Transl Oncol 7(1):101–110CrossRefPubMedPubMedCentral Boes JL, Hoff BA, Hylton N, et al. (2014) Image registration for quantitative parametric response mapping of cancer treatment response. Transl Oncol 7(1):101–110CrossRefPubMedPubMedCentral
22.
go back to reference Choi SJ, Kim J, Seo J, et al. (2014) Parametric response mapping of dynamic CT as an imaging biomarker to distinguish viability of hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Abdom Imaging 39(3):518–525CrossRefPubMed Choi SJ, Kim J, Seo J, et al. (2014) Parametric response mapping of dynamic CT as an imaging biomarker to distinguish viability of hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Abdom Imaging 39(3):518–525CrossRefPubMed
23.
go back to reference Choi SJ, Kim J, Seo J, et al. (2015) Parametric response mapping of dynamic CT for predicting intrahepatic recurrence of hepatocellular carcinoma after conventional transcatheter arterial chemoembolization. Eur Radiol 26:225–234CrossRefPubMed Choi SJ, Kim J, Seo J, et al. (2015) Parametric response mapping of dynamic CT for predicting intrahepatic recurrence of hepatocellular carcinoma after conventional transcatheter arterial chemoembolization. Eur Radiol 26:225–234CrossRefPubMed
24.
go back to reference Dufour JF, Greten TF, Raymond E, et al. (2012) EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56(4):908–943CrossRef Dufour JF, Greten TF, Raymond E, et al. (2012) EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56(4):908–943CrossRef
26.
go back to reference Terzi E, Golfieri R, Piscaglia F, et al. (2012) Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”. J Hepatol 57(6):1258–1267CrossRefPubMed Terzi E, Golfieri R, Piscaglia F, et al. (2012) Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”. J Hepatol 57(6):1258–1267CrossRefPubMed
27.
go back to reference Kim BK, Kim SU, Kim MJ, et al. (2013) Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization. Clin Cancer Res 19:1503–1511CrossRefPubMed Kim BK, Kim SU, Kim MJ, et al. (2013) Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization. Clin Cancer Res 19:1503–1511CrossRefPubMed
28.
go back to reference Shim JH, Lee HC, Won HJ, et al. (2012) Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma. J Hepatol 56:406–411CrossRefPubMed Shim JH, Lee HC, Won HJ, et al. (2012) Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma. J Hepatol 56:406–411CrossRefPubMed
29.
go back to reference Jung ES, Kim JHJS, Yoon EL, et al. (2013) Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol 58(6):1181–1187CrossRefPubMed Jung ES, Kim JHJS, Yoon EL, et al. (2013) Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol 58(6):1181–1187CrossRefPubMed
30.
go back to reference Meyer CR, Boes JL, Kim B, et al. (1997) Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations. Med Image Anal 1(3):195–206CrossRefPubMed Meyer CR, Boes JL, Kim B, et al. (1997) Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations. Med Image Anal 1(3):195–206CrossRefPubMed
31.
go back to reference Georgiades C, Geschwind J-F, Harrison N, et al. (2012) Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology 265(1):115–123CrossRefPubMedPubMedCentral Georgiades C, Geschwind J-F, Harrison N, et al. (2012) Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology 265(1):115–123CrossRefPubMedPubMedCentral
32.
go back to reference Shim JH, Lee HC, Kim S-O, et al. (2012) Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 262(2):708–718CrossRefPubMed Shim JH, Lee HC, Kim S-O, et al. (2012) Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 262(2):708–718CrossRefPubMed
33.
go back to reference Kim SH, Lee WJ, Lim HK, Lim JH (2007) Prediction of viable tumor in hepatocellular carcinoma treated with transcatheter arterial chemoembolization: usefulness of attenuation value measurement at quadruple-phase helical computed tomography. J Comput Assist Tomogr 31(2):198–203CrossRefPubMed Kim SH, Lee WJ, Lim HK, Lim JH (2007) Prediction of viable tumor in hepatocellular carcinoma treated with transcatheter arterial chemoembolization: usefulness of attenuation value measurement at quadruple-phase helical computed tomography. J Comput Assist Tomogr 31(2):198–203CrossRefPubMed
34.
go back to reference Hunt SJ, Yu W, Weintraub J, Prince MR, Kothary N (2009) Radiologic monitoring of hepatocellular carcinoma tumor viability after transhepatic arterial chemoembolization: estimating the accuracy of contrast-enhanced cross-sectional imaging with histopathologic correlation. J Vasc Interv Radiol 20(1):30–38CrossRefPubMed Hunt SJ, Yu W, Weintraub J, Prince MR, Kothary N (2009) Radiologic monitoring of hepatocellular carcinoma tumor viability after transhepatic arterial chemoembolization: estimating the accuracy of contrast-enhanced cross-sectional imaging with histopathologic correlation. J Vasc Interv Radiol 20(1):30–38CrossRefPubMed
35.
go back to reference Lin MingDe, Pellerin Olivier, Bhagat Nikhil, et al. (2012) Quantitative and volumetric EASL and RECIST: feasibility of a semi-automated software method to assess tumor response after transcatheter arterial chemoembolization (TACE). J Vasc Interv Radiol 23(12):1629–1637CrossRefPubMedPubMedCentral Lin MingDe, Pellerin Olivier, Bhagat Nikhil, et al. (2012) Quantitative and volumetric EASL and RECIST: feasibility of a semi-automated software method to assess tumor response after transcatheter arterial chemoembolization (TACE). J Vasc Interv Radiol 23(12):1629–1637CrossRefPubMedPubMedCentral
36.
go back to reference Bargellini I, Scionti A, Mismas V, et al. (2014) Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward? Oncology 86(4):191–198CrossRefPubMed Bargellini I, Scionti A, Mismas V, et al. (2014) Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward? Oncology 86(4):191–198CrossRefPubMed
37.
go back to reference Mannelli L, Kim S, Hajdu CH, et al. (2009) Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. Am J Roentgenol 193(4):1044–1052CrossRef Mannelli L, Kim S, Hajdu CH, et al. (2009) Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. Am J Roentgenol 193(4):1044–1052CrossRef
38.
go back to reference Kim S, Mannelli L, Hajdu CH, et al. (2010) Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 31(2):348–355CrossRefPubMed Kim S, Mannelli L, Hajdu CH, et al. (2010) Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 31(2):348–355CrossRefPubMed
39.
go back to reference Rossi S, Garbagnati F, Lencioni R, et al. (2000) Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 217(1):119–126CrossRefPubMed Rossi S, Garbagnati F, Lencioni R, et al. (2000) Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 217(1):119–126CrossRefPubMed
40.
go back to reference Shim SJ, Seong J, Han KH, et al. (2005) Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int 25(6):1189–1196CrossRefPubMed Shim SJ, Seong J, Han KH, et al. (2005) Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int 25(6):1189–1196CrossRefPubMed
41.
go back to reference Hinrichs J, Shin H, Vogel A, et al. (2016) Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE. Eur Radiol . doi:10.1007/s00330-015-4203-4 Hinrichs J, Shin H, Vogel A, et al. (2016) Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE. Eur Radiol . doi:10.​1007/​s00330-015-4203-4
42.
go back to reference Vilgrain V (2010) Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments. Hepatocellular carcinoma: Imaging in assessing treatment efficacy. J Hepatobiliary Pancreat Sci 17:374–379CrossRefPubMed Vilgrain V (2010) Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments. Hepatocellular carcinoma: Imaging in assessing treatment efficacy. J Hepatobiliary Pancreat Sci 17:374–379CrossRefPubMed
Metadata
Title
Parametric response mapping of dynamic CT: enhanced prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization
Authors
Seung Joon Choi
Jonghoon Kim
Hyung Sik Kim
Hyunjin Park
Publication date
01-07-2017
Publisher
Springer US
Published in
Abdominal Radiology / Issue 7/2017
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-017-1082-y

Other articles of this Issue 7/2017

Abdominal Radiology 7/2017 Go to the issue

Classics in Abdominal Imaging

Liver scalloping in pseudomyxoma peritonei

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.